Histide is a Swiss biotech and intellectual property (IP) platform company pioneering a new class of nonmutagenic extracellular therapeutic agents called Cell Recoding Molecules (CRMs). CRMs promote and stimulate cells’ natural capacity to redirect their own fate by integrating extracellular signals. CRMs are at the heart of Histide’s groundbreaking approach to addressing diseases called Recoding Therapeutics, which goes beyond traditional cell-, gene- or RNA-based therapies. This innovative platform builds on Histide’s expertise in the mechanisms underlying cells’ microenvironmental sensing and signal transduction processes.
Based in the Zurich metropolitan area, Histide was founded in 2014. Histide has since assembled an experienced management team together with visionary scientists, all committed to providing enhanced therapeutic solutions toward patient healing and quality of life.
From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.